Cargando…

Nonmetastatic Castration-Resistant Prostate Cancer: Current Challenges and Trends

Prostate carcinoma is a highly prevalent biologically and clinically diverse disease, generally associated with a consistent elevation of prostate-specific antigen levels. Castration-resistant prostate cancer represents a heterogeneous clinical setting that ranges from patients with an asymptomatic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Figueiredo, Arnaldo, Costa, Luís, Maurício, Maria Joaquina, Figueira, Luís, Ramos, Rodrigo, Martins-da-Silva, Carlos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2022
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9338100/ https://www.ncbi.nlm.nih.gov/pubmed/35829924 http://dx.doi.org/10.1007/s40261-022-01178-y

Ejemplares similares

Correction to: Nonmetastatic Castration‑Resistant Prostate Cancer: Current Challenges and Trends
por: Figueiredo, Arnaldo, et al.
Publicado: (2022)

Correction to: Nonmetastatic Castration‑Resistant Prostate Cancer: Current Challenges and Trends
por: Figueiredo, Arnaldo, et al.
Publicado: (2023)

Nonmetastatic Castration-Resistant Prostate Cancer
por: Hong, Jun Hyuk, et al.
Publicado: (2014)

Apalutamide for the Treatment of Nonmetastatic Castration-Resistant Prostate Cancer
por: Patel, Urvi J., et al.
Publicado: (2019)

Budget Impact of Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer
por: Schultz, Neil M., et al.
Publicado: (2020)

Enzalutamide: a new indication for nonmetastatic castration-resistant prostate cancer
por: Rhea, Logan P, et al.
Publicado: (2019)

Denosumab: Delay of bone metastasis in men with nonmetastatic castrate-resistant prostate cancer
por: Manger, Jules P., et al.
Publicado: (2012)

Treatment Landscape of Nonmetastatic Castration-Resistant Prostate Cancer: A Window of Opportunity
por: López-Campos, Fernando, et al.
Publicado: (2021)

Survival Outcomes by Race and Ethnicity in Veterans With Nonmetastatic Castration-Resistant Prostate Cancer
por: Rasmussen, Kelli M., et al.
Publicado: (2023)

Budget impact analysis of darolutamide for treatment of nonmetastatic castration-resistant prostate cancer
por: Appukkuttan, Sreevalsa, et al.
Publicado: (2021)

Pilot Phase II Trial of Bevacizumab Monotherapy in Nonmetastatic Castrate-Resistant Prostate Cancer
por: Ogita, Shin, et al.
Publicado: (2012)

Patient and caregiver benefit‐risk preferences for nonmetastatic castration‐resistant prostate cancer treatment
por: Srinivas, Sandy, et al.
Publicado: (2020)

Darolutamide: a novel androgen-signaling agent in nonmetastatic castration-resistant prostate cancer
por: Aragon-Ching, Jeanny B
Publicado: (2019)

Nonmetastatic castration-resistant prostate cancer: Novel agents to treat a lethal disease
por: Henriquez, Ivan, et al.
Publicado: (2021)

Real-world use of enzalutamide in men with nonmetastatic castration-resistant prostate cancer in Japan
por: Yokomizo, Akira, et al.
Publicado: (2021)

Time to castration resistance is a novel prognostic factor of cancer-specific survival in patients with nonmetastatic castration-resistant prostate cancer
por: Hakozaki, Yuji, et al.
Publicado: (2022)

Correction to: Real-world use of enzalutamide in men with nonmetastatic castration-resistant prostate cancer in Japan
por: Yokomizo, Akira, et al.
Publicado: (2022)

Treatment of nonmetastatic castration-resistant prostate cancer: focus on second-generation androgen receptor inhibitors
por: Saad, Fred, et al.
Publicado: (2021)

Association of Molecular Subtypes With Differential Outcome to Apalutamide Treatment in Nonmetastatic Castration-Resistant Prostate Cancer
por: Feng, Felix Y., et al.
Publicado: (2021)

The ARAMIS trial: Why Darolutamide is better than apalutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer
por: Tripathy, Sambit
Publicado: (2021)

Apalutamide, Darolutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC): A Critical Review
por: Cattrini, Carlo, et al.
Publicado: (2022)

Nonmetastatic castration‐resistant prostate cancer treated with salvage focal brachytherapy after external beam radiotherapy
por: Yoshida, Soichiro, et al.
Publicado: (2021)

Understanding Treatment Strategies and Preferences in Nonmetastatic Castration-Resistant Prostate Cancer From the Japanese Physician Perspective
por: Suzuki, Kazuhiro, et al.
Publicado: (2021)

Consensus on the Treatment and Follow-Up for the Nonmetastatic Castration-Resistant Prostate Cancer: A Report From the First Prostate Cancer Consensus Conference for Developing Countries
por: Pereira, Felipe Moraes Toledo, et al.
Publicado: (2021)

Editorial Comment to Nonmetastatic castration‐resistant prostate cancer treated with salvage focal brachytherapy after external beam radiotherapy
por: Hirayama, Yukiyoshi, et al.
Publicado: (2021)

Bone health effects of androgen-deprivation therapy and androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer
por: Hussain, Arif, et al.
Publicado: (2020)

Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial
por: Penson, David F., et al.
Publicado: (2021)

Matching-adjusted indirect treatment comparison of the efficacy of enzalutamide versus apalutamide for the treatment of nonmetastatic castration-resistant prostate cancer
por: Tombal, B., et al.
Publicado: (2022)

Real‑world survival outcome comparing abiraterone acetate plus prednisone and enzalutamide for nonmetastatic castration‐resistant prostate cancer
por: Tsujino, Takuya, et al.
Publicado: (2023)

Correction: Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial
por: Penson, David F., et al.
Publicado: (2021)

Effects of once-yearly zoledronic acid on bone density and incident vertebral fractures in nonmetastatic castration-sensitive prostate cancer patients with osteoporosis
por: Watanabe, Daisuke, et al.
Publicado: (2021)

Current Role of Chemotherapy in Nonmetastatic Nasopharyngeal Cancer
por: Bhattacharyya, Tapesh, et al.
Publicado: (2018)

Efficacy and safety of darolutamide in Japanese patients with nonmetastatic castration-resistant prostate cancer: a sub-group analysis of the phase III ARAMIS trial
por: Uemura, Hiroji, et al.
Publicado: (2020)

The utility of [(18)F]Fluciclovine PET/CT in Evaluating Nonmetastatic Castrate-Resistant Prostate Cancer Patients (nmCRPCp): diagnostic performance and impact on management
por: Soliman, Moataz, et al.
Publicado: (2023)

Castration-Resistant Prostate Cancer: Mechanisms, Targets, and Treatment
por: Amaral, Teresa Maria Santos, et al.
Publicado: (2012)

Efficacy and safety of apalutamide in Japanese patients with nonmetastatic castration-resistant prostate cancer: a subgroup analysis of a randomized, double-blind, placebo-controlled, Phase-3 study
por: Uemura, Hiroji, et al.
Publicado: (2020)

(68)Ga-PSMA-11 PET/CT in restaging castration-resistant nonmetastatic prostate cancer: detection rate, impact on patients’ disease management and adequacy of impact
por: Fourquet, Aloÿse, et al.
Publicado: (2020)

Current Treatment Strategies for Castration-Resistant Prostate Cancer
por: Kim, Se Joong, et al.
Publicado: (2011)

“Prostate telocytes change their phenotype in response to castration or testosterone replacement”
por: Felisbino, Sérgio Luis, et al.
Publicado: (2019)

Metastatic castration-resistant prostate cancer and the challenge of a patient with chronic kidney disease in hemodialysis
por: Simões, Joana, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_j5jg1d6hq5jl3m00l28ej0r0lj